Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644351 · ClinicalTrials.gov registry record
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 37
- Enrollment target
NCT07644351 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT07644351 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2025-09-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07644351
The ClinicalTrials.gov registry entry for NCT07644351 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07644351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07644351 about?
NCT07644351 is a clinical study titled "A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients". The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or ...
What is the current status of trial NCT07644351?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2024-12-16. Estimated completion is 2025-09-17.
Who is sponsoring clinical trial NCT07644351?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.